ABSTRACT A number of pharmacologic or genetic interventions have been shown to prevent the development of fibrosis following the intratracheal administration of bleomycin, a commonly used model for the study of lung fibrosis. These studies have provided important mechanistic insights into the development of pulmonary fibrosis and have identified both transforming growth factor-beta (TGF-beta) and peroxsome prolifeatoractivated receptor-gamma (PPAR-gamma) as important mediators of fibrosis. In our preliminary data, we observed that the administration of a proteasome inhibitor to mice 8 days after the administration of bleomycin resulted in marked attenuation of lung fibrosis. Similar protection was observed in a bleomycin induced skin fibrosis model of scleroderma. Additional preliminary data suggest that proteasomal inhibition results in increased abundance and activity of PPAR-gamma, which functions as an inhibitor of TGF-beta. We hypothesize that the administration of proteasomal inhibitors prevents the ubiquitin-mediated degradation of PPAR-Gamma in normal human lung fibroblasts and in the mouse lung thereby inhibiting the transcriptional response to active TGF-beta and attenuating fibrosis. We have generated three interrelated specific aims to identify the molecular mechanisms by which PPAR-gamma is degraded and by which this degradation is accelerated in the presence of TGF-beta. Aim 1. Is PPAR-gamma required for inhibition of the transcriptional response to active TGF-beta induced by proteasomal inhibition in normal human lung fibroblasts? Aim 2. How is PPAR-gamma targeted for proteasomal degradation in normal human lung fibroblasts? Aim 3. Does the bortezomibmediated increase in the protein abundance of PPAR-gamma prevent the development of lung fibrosis in mice treated with bleomycin downstream of the activation of TGF- beta1? This application represents a highly innovative effort that employs molecular tools in cell culture systems and sophisticated mouse models to elucidate the mechanisms by which proteasomal inhibition might prevent the development of pulmonary fibrosis. Our preliminary data support the feasibility of the proposed experiments and provide support for our focus on the ubiquitin-proteasomal system’s regulation of PPAR-gamma.
|Effective start/end date||10/1/12 → 5/31/15|
- Jesse Brown VA Medical Center (Agreement Date: 11/8/13)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.